FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068132005> ?p ?o ?g. }

• W2068132005 endingPage "1408" @default.
• W2068132005 startingPage "1403" @default.
• W2068132005 abstract "Bortezomib, a selective 26S proteasome inhibitor, has shown clinical benefits against refractory multiple myeloma. The indirect anti-angiogenic activity of bortezomib has been widely recognized; however, the growth-inhibitory mechanism of bortezomib on vascular endothelial cells remains unclear, especially on the cell cycle. Here, we showed that bortezomib (2 nM of the IC(50) value) potently inhibited the cellular growth of human umbilical vascular endothelial cells (HUVECs) via a vascular endothelial growth factor receptor (VEGFR)-independent mechanism resulting in the induction of apoptosis. Bortezomib significantly increased the vascular permeability of HUVECs, whereas a VEGFR-2 tyrosine kinase inhibitor decreased it. Interestingly, a cell cycle analysis using flow cytometry, the immunostaining of phospho-histone H3, and Giemsa staining revealed that bortezomib suppressed the G2/M transition of HUVECs, whereas the mitotic inhibitor paclitaxel induced M-phase accumulation. A further analysis of cell cycle-related proteins revealed that bortezomib increased the expression levels of cyclin B1, the cdc2/cyclin B complex, and the phosphorylation of all T14, Y15, and T161 residues on cdc2. Bortezomib also increased the ubiquitination of cyclin B1 and wee1, but inhibited the kinase activity of the cdc2/cyclin B complex. These protein modifications support the concept that bortezomib suppresses the G2/M transition, rather than causing M-phase arrest. In conclusion, we demonstrated that bortezomib potently inhibits cell growth by suppressing the G2/M transition, modifying G2/M-phase-related cycle regulators, and increasing the vascular permeability of vascular endothelial cells. Our findings reveal a cell cycle-related mode of action and strongly suggest that bortezomib exerts an additional unique vascular disrupting effect as a vascular targeting drug." @default.
• W2068132005 created "2016-06-24" @default.
• W2068132005 creator A5000324980 @default.
• W2068132005 creator A5002405384 @default.
• W2068132005 creator A5004282323 @default.
• W2068132005 creator A5010652134 @default.
• W2068132005 creator A5013490553 @default.
• W2068132005 creator A5036363193 @default.
• W2068132005 creator A5041182728 @default.
• W2068132005 creator A5042062725 @default.
• W2068132005 creator A5058549884 @default.
• W2068132005 creator A5062818098 @default.
• W2068132005 creator A5074728680 @default.
• W2068132005 creator A5083384491 @default.
• W2068132005 creator A5087401551 @default.
• W2068132005 date "2010-05-19" @default.
• W2068132005 modified "2023-10-18" @default.
• W2068132005 title "Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition" @default.
• W2068132005 cites W1519096021 @default.
• W2068132005 cites W1798928306 @default.
• W2068132005 cites W1966255005 @default.
• W2068132005 cites W1966726954 @default.
• W2068132005 cites W1970831375 @default.
• W2068132005 cites W2002223631 @default.
• W2068132005 cites W2007687296 @default.
• W2068132005 cites W2015997780 @default.
• W2068132005 cites W2033715459 @default.
• W2068132005 cites W2038250066 @default.
• W2068132005 cites W2074423119 @default.
• W2068132005 cites W2085901921 @default.
• W2068132005 cites W2092169550 @default.
• W2068132005 cites W2102782790 @default.
• W2068132005 cites W2103763724 @default.
• W2068132005 cites W2108691268 @default.
• W2068132005 cites W2114024312 @default.
• W2068132005 cites W2116090592 @default.
• W2068132005 cites W2124560610 @default.
• W2068132005 cites W2136735139 @default.
• W2068132005 cites W2138919514 @default.
• W2068132005 cites W2158794607 @default.
• W2068132005 cites W2163498786 @default.
• W2068132005 cites W2166987747 @default.
• W2068132005 doi "https://doi.org/10.1111/j.1349-7006.2010.01544.x" @default.
• W2068132005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20367638" @default.
• W2068132005 hasPublicationYear "2010" @default.
• W2068132005 type Work @default.
• W2068132005 sameAs 2068132005 @default.
• W2068132005 citedByCount "52" @default.
• W2068132005 countsByYear W20681320052012 @default.
• W2068132005 countsByYear W20681320052013 @default.
• W2068132005 countsByYear W20681320052014 @default.
• W2068132005 countsByYear W20681320052015 @default.
• W2068132005 countsByYear W20681320052016 @default.
• W2068132005 countsByYear W20681320052017 @default.
• W2068132005 countsByYear W20681320052019 @default.
• W2068132005 countsByYear W20681320052020 @default.
• W2068132005 countsByYear W20681320052021 @default.
• W2068132005 countsByYear W20681320052022 @default.
• W2068132005 countsByYear W20681320052023 @default.
• W2068132005 crossrefType "journal-article" @default.
• W2068132005 hasAuthorship W2068132005A5000324980 @default.
• W2068132005 hasAuthorship W2068132005A5002405384 @default.
• W2068132005 hasAuthorship W2068132005A5004282323 @default.
• W2068132005 hasAuthorship W2068132005A5010652134 @default.
• W2068132005 hasAuthorship W2068132005A5013490553 @default.
• W2068132005 hasAuthorship W2068132005A5036363193 @default.
• W2068132005 hasAuthorship W2068132005A5041182728 @default.
• W2068132005 hasAuthorship W2068132005A5042062725 @default.
• W2068132005 hasAuthorship W2068132005A5058549884 @default.
• W2068132005 hasAuthorship W2068132005A5062818098 @default.
• W2068132005 hasAuthorship W2068132005A5074728680 @default.
• W2068132005 hasAuthorship W2068132005A5083384491 @default.
• W2068132005 hasAuthorship W2068132005A5087401551 @default.
• W2068132005 hasBestOaLocation W20681320051 @default.
• W2068132005 hasConcept C120504264 @default.
• W2068132005 hasConcept C124320809 @default.
• W2068132005 hasConcept C1491633281 @default.
• W2068132005 hasConcept C16438837 @default.
• W2068132005 hasConcept C185592680 @default.
• W2068132005 hasConcept C199835354 @default.
• W2068132005 hasConcept C203014093 @default.
• W2068132005 hasConcept C27740335 @default.
• W2068132005 hasConcept C2776364478 @default.
• W2068132005 hasConcept C2777478702 @default.
• W2068132005 hasConcept C2778367456 @default.
• W2068132005 hasConcept C2778437423 @default.
• W2068132005 hasConcept C29537977 @default.
• W2068132005 hasConcept C502942594 @default.
• W2068132005 hasConcept C55493867 @default.
• W2068132005 hasConcept C62112901 @default.
• W2068132005 hasConcept C86803240 @default.
• W2068132005 hasConcept C95444343 @default.
• W2068132005 hasConcept C9743823 @default.
• W2068132005 hasConceptScore W2068132005C120504264 @default.
• W2068132005 hasConceptScore W2068132005C124320809 @default.
• W2068132005 hasConceptScore W2068132005C1491633281 @default.
• W2068132005 hasConceptScore W2068132005C16438837 @default.
• W2068132005 hasConceptScore W2068132005C185592680 @default.

• next